Xia Xu Gang, Zhou Hongxia, Xu Zuoshang
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, 01605, USA.
Neurodegener Dis. 2005;2(3-4):220-31. doi: 10.1159/000089629.
RNA interference (RNAi) is a recently discovered mechanism that is conserved in a wide range of eukaryotic species. Triggered by double-stranded RNA, RNAi identifies and destroys the mRNA that shares homology with the double-stranded RNA. Because of its specificity, RNAi has a high potential for being a powerful investigative and therapeutic tool. Indeed, its use as a reverse genetics tool to determine gene functions in invertebrates and cultured mammalian cells has already been experiencing an explosive growth. Gratifyingly we have also seen its application in dissecting neurodegeneration pathways in vitro. Although early studies suggested that RNAi could be readily adapted for in vivo studies in mammals using the transgenic technology, difficulties including low transgenicity and low RNAi efficacy have emerged, which has prevented the wide use of transgenic RNAi. The potential of RNAi therapy for human diseases has been a great source of excitement. Several new studies have demonstrated this concept in animal models of neurodegenerative disease. In this review, we highlight the recent literature and our own data in applying RNAi in research and therapy in the area of neurodegenerative diseases. We discuss the present and future challenges in the full realization of the potential for RNAi.
RNA干扰(RNAi)是一种最近发现的机制,在广泛的真核生物物种中保守存在。由双链RNA触发,RNAi识别并破坏与双链RNA具有同源性的mRNA。由于其特异性,RNAi具有成为强大的研究和治疗工具的巨大潜力。实际上,它作为一种反向遗传学工具用于确定无脊椎动物和培养的哺乳动物细胞中的基因功能,其应用已经呈爆发式增长。令人欣慰的是,我们也看到了它在体外剖析神经退行性变途径中的应用。尽管早期研究表明,利用转基因技术RNAi可以很容易地应用于哺乳动物的体内研究,但包括低转基因性和低RNAi效率在内的困难已经出现,这阻碍了转基因RNAi的广泛应用。RNAi疗法治疗人类疾病的潜力一直是令人兴奋的一大来源。几项新的研究已经在神经退行性疾病的动物模型中证明了这一概念。在这篇综述中,我们重点介绍了最近的文献以及我们自己在神经退行性疾病领域将RNAi应用于研究和治疗的数据。我们讨论了在充分实现RNAi潜力方面当前和未来面临的挑战。